公开(公告)号：US08871466B2

公开(公告)日：2014-10-28

申请号：US14126091

申请日：2012-06-13

Applicant: Hong Jin Kim ,  Hyoung Jin Kim

Inventor： Hong Jin Kim ,  Hyoung Jin Kim

IPC: C12P21/02 ,  C12N1/18 ,  C07K14/005

CPC classification number: C07K14/005 ,  C12N1/18 ,  C12N2710/20022 ,  C12N2710/20051 ,  C12P21/02

Abstract: This invention is a method for improving production yield of HPV L1 protein including the phase of culturing cell expressing HPV L1 protein in a medium containing high concentration of carbon source. According to the culture method using a medium containing highly concentrated carbon source of this invention, the production yield of HPV L1 protein can be not only remarkably increased but also the immunogenicity of the produced HPV L1 protein is significantly increased.

Abstract translation: 本发明是提高含有高浓度碳源的培养基中HPV L1蛋白的培养细胞相的HPV L1蛋白的生产率的方法。 根据使用含有本发明的高浓度碳源的培养基的培养方法，HPV L1蛋白的生产率不仅显着增加，而且HPV L1蛋白的免疫原性显着增加。

公开(公告)号：US09994618B2

公开(公告)日：2018-06-12

申请号：US14418004

申请日：2013-07-30

Applicant: Hong-Jin Kim

Inventor： Hong-Jin Kim ,  Hyoung Jin Kim

IPC: C07K14/005 ,  C07K14/025 ,  C12N7/00 ,  C12N7/02 ,  A61K39/00 ,  A61K39/12

CPC classification number: C07K14/005 ,  A61K39/00 ,  C12N7/00 ,  C12N2710/20034 ,  C12N2710/20051

Abstract: Provided is a method of purifying human papillomavirus (HPV) L1 proteins with high purity and high efficiency. According to the purification method, a purification purity and yield of HPV L1 proteins can be considerably increased when heating/chilling is formed by treating a cell homogenate with a reducing agent. In addition, VLPs of the HPV L1 protein purified by the purification method have excellent antigenicity and immunogenicity.

公开(公告)号：US20150266927A1

公开(公告)日：2015-09-24

申请号：US14418004

申请日：2013-07-30

Applicant: Hong-Jin KIM

Inventor： Hong-Jin Kim ,  Hyoung Jin Kim

IPC: C07K14/005 ,  C12N7/00

CPC classification number: C07K14/005 ,  A61K39/00 ,  C12N7/00 ,  C12N2710/20034 ,  C12N2710/20051

Abstract: Provided is a method of purifying human papillomavirus (HPV) L1 proteins with high purity and high efficiency. According to the purification method, a purification purity and yield of HPV L1 proteins can be considerably increased when heating/chilling is formed by treating a cell homogenate with a reducing agent. In addition, VLPs of the HPV L1 protein purified by the purification method have excellent antigenicity and immunogenicity.

Abstract translation: 提供了一种纯化和高效率纯化人乳头状瘤病毒（HPV）L1蛋白的方法。 根据纯化方法，当通过用还原剂处理细胞匀浆而加热/冷却时，可以显着增加HPV L1蛋白的纯化纯度和产率。 此外，通过纯化方法纯化的HPV L1蛋白的VLP具有优异的抗原性和免疫原性。

公开(公告)号：US20120100169A1

公开(公告)日：2012-04-26

申请号：US13379212

申请日：2009-10-20

Applicant: Hong-Jin Kim ,  Na Gyong Lee ,  Yang-Je Cho ,  Jin-Wook Jang ,  Hyoung Jin Kim ,  Kwang Sung Kim

Inventor： Hong-Jin Kim ,  Na Gyong Lee ,  Yang-Je Cho ,  Jin-Wook Jang ,  Hyoung Jin Kim ,  Kwang Sung Kim

IPC: A61K39/12 ,  A61P35/00 ,  C12N1/19 ,  A61P37/04 ,  C12P21/02 ,  C12N15/37

CPC classification number: A61K39/12 ,  A61K39/39 ,  A61K2039/5258 ,  A61K2039/55505 ,  A61K2039/55572 ,  A61K2039/70 ,  C12N2710/20023 ,  C12N2710/20034

Abstract: The present invention relates to a pharmaceutical vaccine composition for a human cervical cancer, comprising: (a) (i) a L1 virus-like particle (VLP) of human papillomavirus (HPV) type 16, a L1 VLP of HPV type 18, or a combination thereof; and (ii) a deacylated non-toxic lipooligosaccharide (LOS); and (b) a pharmaceutically acceptable carrier; and a method for preparing a human papillomavirus (HPV) L1 virus-like particle (VLP). The pharmaceutical vaccine composition of the present invention is in both Th1-type immune response (cellular immunity) and Th2-type immune response (humoral immunity) against HPV more excellent than Cervrix™ and Gardasil™, exhibiting a superior efficacy as a vaccine for a human cervical cancer.

Abstract translation: 本发明涉及用于人宫颈癌的药物疫苗组合物，其包括：（i）（i）16型人乳头状瘤病毒（HPV）的L1病毒样颗粒（VLP），HPV 18型的L1 VLP或 其组合; 和（ii）脱酰无毒低密度寡糖（LOS）; 和（b）药学上可接受的载体; 以及制备人乳头状瘤病毒（HPV）L1病毒样颗粒（VLP）的方法。 本发明的药物疫苗组合物具有比Cervrix TM和Gardasil TM更优异的Th1型免疫应答（细胞免疫）和对HPV的Th2型免疫应答（体液免疫），表现出作为疫苗的优异功效 人宫颈癌。

公开(公告)号：US20140186888A1

公开(公告)日：2014-07-03

申请号：US14126091

申请日：2012-06-13

Applicant: Hong Jin Kim ,  Hyoung Jin Kim

Inventor： Hong Jin Kim ,  Hyoung Jin Kim

IPC: C07K14/005

CPC classification number: C07K14/005 ,  C12N1/18 ,  C12N2710/20022 ,  C12N2710/20051 ,  C12P21/02

Abstract: This invention is a method for improving production yield of HPV L1 protein including the phase of culturing cell expressing HPV L1 protein in a medium containing high concentration of carbon source. According to the culture method using a medium containing highly concentrated carbon source of this invention, the production yield of HPV L1 protein can be not only remarkably increased but also the immunogenicity of the produced HPV L1 protein is significantly increased.

Abstract translation: 本发明是提高含有高浓度碳源的培养基中HPV L1蛋白的培养细胞相的HPV L1蛋白的生产率的方法。 根据使用含有本发明的高浓度碳源的培养基的培养方法，HPV L1蛋白的生产率不仅显着增加，而且HPV L1蛋白的免疫原性显着增加。

公开(公告)号：US09566323B2

公开(公告)日：2017-02-14

申请号：US13379212

申请日：2009-10-20

Applicant: Hong-Jin Kim ,  Na Gyong Lee ,  Yang-Je Cho ,  Jin-Wook Jang ,  Hyoung Jin Kim ,  Kwang Sung Kim

Inventor： Hong-Jin Kim ,  Na Gyong Lee ,  Yang-Je Cho ,  Jin-Wook Jang ,  Hyoung Jin Kim ,  Kwang Sung Kim

IPC: A61K39/12 ,  A61K39/39 ,  A61K39/00

CPC classification number: A61K39/12 ,  A61K39/39 ,  A61K2039/5258 ,  A61K2039/55505 ,  A61K2039/55572 ,  A61K2039/70 ,  C12N2710/20023 ,  C12N2710/20034

Abstract: The present invention relates to a pharmaceutical vaccine composition for a human cervical cancer, comprising: (a) (i) a L1 virus-like particle (VLP) of human papillomavirus (HPV) type 16, a L1 VLP of HPV type 18, or a combination thereof; and (ii) a deacylated non-toxic lipooligosaccharide (LOS); and (b) a pharmaceutically acceptable carrier; and a method for preparing a human papillomavirus (HPV) L1 virus-like particle (VLP). The pharmaceutical vaccine composition of the present invention is in both Th1-type immune response (cellular immunity) and Th2-type immune response (humoral immunity) against HPV more excellent than Cervrix™ and Gardasil™, exhibiting a superior efficacy as a vaccine for a human cervical cancer.

Abstract translation: 本发明涉及用于人宫颈癌的药物疫苗组合物，其包括：（i）（i）16型人乳头状瘤病毒（HPV）的L1病毒样颗粒（VLP），HPV 18型的L1 VLP或 其组合; 和（ii）脱酰无毒低密度寡糖（LOS）; 和（b）药学上可接受的载体; 以及制备人乳头状瘤病毒（HPV）L1病毒样颗粒（VLP）的方法。 本发明的药物疫苗组合物具有比Cervrix TM和Gardasil TM更优异的Th1型免疫应答（细胞免疫）和对HPV的Th2型免疫应答（体液免疫），表现出作为疫苗的优异功效 人宫颈癌。